CSL's $11.7B buyout hits antitrust delay — is it a sign of what's to come?

Nicole DeFeudis

Editor

CSL’s mammoth Vifor Pharma buyout will have to wait a few more months, the company revealed on Wednesday, as experts wonder whether antitrust regulators will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CSL's $11.7B buyout hits antitrust delay — is it a sign of what's to come?

Nicole DeFeudis

Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Are programs with compounded GLP-1s safe for your population?

CSL's $11.7B buy­out hits an­titrust de­lay — is it a sign of what's to come?

Nicole DeFeudis

Editor

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

CSL's $11.7B buyout hits antitrust delay — is it a sign of what's to come?

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

Are programs with compounded GLP-1s safe for your population?